STAT6 and Fabry disease: Other anti-inflammatory treatments that target duodenal eosinophil recruitment and activation, such as monoclonal antibodies against Th2-derived cytokines (Stein et al., 2006; Straumann et al., 2010; Rothenberg et al., 2015; Hirano et al., 2020), anti-α4β7 integrin antibody (Bochner, 2000; Grandinetti et al., 2019), and Janus kinase/STAT6 pathway inhibitors (Cheng et al., 2016), are also anticipated for FD patients.